|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received on September 3, 2004
Accepted on November 2, 2004
Endocrinology and Metabolism |
yna Chwatko 1
1 Department of Microbiology and Molecular Genetics, UMDNJ-New Jersey Medical School, International Center for Public Health, Newark, NJ, and Permanent affiliation: Department of Environmental Chemistry, University of Lód
, Lód
, Poland
2 Department of Microbiology and Molecular Genetics, UMDNJ-New Jersey Medical School, International Center for Public Health, Newark, NJ, and Institute of Bioorganic Chemistry, Polish Academy of Sciences, Pozna
, Poland
* To whom correspondence should be addressed. E-mail: jakubows{at}umdnj.edu.
Background: A metabolite of homocysteine (Hcy), the thioester Hcy-thiolactone, has been implicated in coronary heart disease in humans. Because inadvertent reactions of Hcy-thiolactone with proteins can lead to cell and tissue damage, the ability to detoxify or eliminate Hcy-thiolactone is essential for biological integrity. We examined the hypothesis that the human body eliminates Hcy-thiolactone by urinary excretion.
Methods: We used a sensitive HPLC method with postcolumn derivatization and fluorescence detection to examine Hcy-thiolactone concentrations in human urine and plasma.
Results: We discovered a previously unknown pool of Hcy-thiolactone in human urine. Urinary concentrations of Hcy-thiolactone (11-485 nmol/L; n = 19) were
100-fold higher than those in plasma (<0.05-22.6 nmol/L; n = 20). Urinary Hcy-thiolactone accounted for 2.5-28.3% of urinary total Hcy, whereas plasma Hcy-thiolactone accounted for <0.002-0.29% of plasma total Hcy. Urinary concentrations of Hcy-thiolactone, but not of total Hcy, were negatively correlated with urinary pH. Clearance of Hcy-thiolactone, relative to creatinine, was 0.21-6.96. In contrast, relative clearance of Hcy was 0.001-0.003.
Conclusions: The analytical methods described here can be used to quantify Hcy-thiolactone in biological fluids. Using these methods we showed that the human body eliminates Hcy-thiolactone by urinary excretion. Our data also suggest that the protonation status of its amino group affects Hcy-thiolactone excretion.
The following articles in journals at HighWire Press have cited this article:
![]() |
H. Jakubowski, J. Perla-Kajan, R. H. Finnell, R. M. Cabrera, H. Wang, S. Gupta, W. D. Kruger, J. P. Kraus, and D. M. Shih Genetic or nutritional disorders in homocysteine or folate metabolism increase protein N-homocysteinylation in mice FASEB J, June 1, 2009; 23(6): 1721 - 1727. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Jakubowski, G. H. J. Boers, and K. A. Strauss Mutations in cystathionine {beta}-synthase or methylenetetrahydrofolate reductase gene increase N-homocysteinylated protein levels in humans FASEB J, December 1, 2008; 22(12): 4071 - 4076. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Dever and A. A. Elfarra L-Methionine Toxicity in Freshly Isolated Mouse Hepatocytes Is Gender-Dependent and Mediated in Part by Transamination J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 809 - 817. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Akahoshi, C. Kobayashi, Y. Ishizaki, T. Izumi, T. Himi, M. Suematsu, and I. Ishii Genetic background conversion ameliorates semi-lethality and permits behavioral analyses in cystathionine {beta}-synthase-deficient mice, an animal model for hyperhomocysteinemia Hum. Mol. Genet., July 1, 2008; 17(13): 1994 - 2005. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Jakubowski Pathophysiological Consequences of Homocysteine Excess J. Nutr., June 1, 2006; 136(6): 1741S - 1749S. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |